232 related articles for article (PubMed ID: 33649847)
21. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol inhibits phosphorylation within the signal transduction and activator of transcription 3 signaling pathway by activating sirtuin 1 in SW1353 chondrosarcoma cells.
Jin H; Chen H; Yu K; Zhang J; Li B; Cai N; Pan J
Mol Med Rep; 2016 Sep; 14(3):2685-90. PubMed ID: 27484919
[TBL] [Abstract][Full Text] [Related]
23. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
24. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.
Chi Z; Gao H; Liu H; Wu B; Zhang B; Gu M; Yang W
Mol Med Rep; 2020 Feb; 21(2):936-944. PubMed ID: 31974619
[TBL] [Abstract][Full Text] [Related]
25. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
26. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2020 Jun; 25(5-6):370-387. PubMed ID: 32394008
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
28. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Yuan XG; Huang YR; Yu T; Jiang HW; Xu Y; Zhao XY
Oncol Lett; 2019 Jul; 18(1):411-419. PubMed ID: 31289512
[TBL] [Abstract][Full Text] [Related]
29. Chidamide alleviates TGF-β-induced epithelial-mesenchymal transition in lung cancer cell lines.
Lin SH; Wang BY; Lin CH; Chien PJ; Wu YF; Ko JL; Chen JJ
Mol Biol Rep; 2016 Jul; 43(7):687-95. PubMed ID: 27188428
[TBL] [Abstract][Full Text] [Related]
30. Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
Liang S; Zhou X; Cai D; Rodrigues-Lima F; Wang L
Curr Pharm Des; 2021; 27(26):2990-2998. PubMed ID: 34218775
[TBL] [Abstract][Full Text] [Related]
31. Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
Lu CT; Leong PY; Hou TY; Huang SJ; Hsiao YP; Ko JL
Phytomedicine; 2018 Dec; 51():39-47. PubMed ID: 30466626
[TBL] [Abstract][Full Text] [Related]
32. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
[TBL] [Abstract][Full Text] [Related]
33. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
Cao HY; Li L; Xue SL; Dai HP
Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
[TBL] [Abstract][Full Text] [Related]
34. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
[TBL] [Abstract][Full Text] [Related]
35. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
[TBL] [Abstract][Full Text] [Related]
36. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
37. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
39. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
[TBL] [Abstract][Full Text] [Related]
40. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.
Li X; He Z; Cheng B; Fang Q; Ma D; Lu T; Wei D; Kuang X; Tang S; Xiong J; Wang J
Cancer Biol Ther; 2018; 19(9):825-834. PubMed ID: 29969367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]